On Monday (September 20), Pfizer and BioNTech revealed the first results from a study with the vaccines.
Good news! According to Pfizer/BioNTech's studies, their COVID-19 vaccines are good for children from 5 to 11.
The company is looking for approval from the Food and Drug Administration and other agencies soon. Pfizer revealed the first results of their studies saying that there was a "favorable safety profile and robust neutralizing antibody responses." They added that the "vaccine was safe, well-tolerated" among the kids.
"Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," said Albert Bourla, chairman and CEO of Pfizer.
"Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. — underscoring the public health need for vaccination," Bourla continued. "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."